AlloVir (NASDAQ:ALVR) layoffs are in the news after the clinical-stage cell therapy company announced a massive number of job cuts. AlloVir has revealed that a new round of layoffs will have it ...

After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration. Kalaris is a clinical-stage biopharmaceutical company ...

What is the current share price of AlloVir Inc (ALVR)? AlloVir Inc's (ALVR) current share price is $9.28. This constitutes a price movement of 2,013.41% when compared to the share price 7 days ago and ...

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired AlloVir, Inc. (NASDAQ: ALVR ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AlloVir, Inc. (NASDAQ: ALVR) and Kalaris Therapeutics is fair to AlloVir shareholders.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares ...

ALVR allows you to play a one-handed version of Beat Saber. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Oculus Go is a standalone wireless VR ...

AlloVir, Inc. ALVR announced that it has initiated a phase III study evaluating its allogeneic, off-the-shelf, multi-virus-specific T-cell therapy, posoleucel, which is being developed for addressing ...

Every investor in AlloVir, Inc. (NASDAQ:ALVR) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, ...